Inhibition of TGF-β1-induced Epithelial-mesenchymal Transition in Gliomas by DMC-HA

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2023 Dec 28

PMID 38154100

Authors

Lei Shi

Zhimin Wang

Jun Rong

Xifeng Fei

Xuetao Li

Bao He

Weiyi Gong

Jin Qian

Affiliations

Soon will be listed here.

Abstract

DMC-HA, a novel HDAC inhibitor, has previously demonstrated antiproliferative activity against various cancers, including gliomas. However, the role of DMC-HA in the regulation of EMT and its underlying mechanisms remain unknown. This study aimed to explore the effects of DMC-HA on TGF-β1-induced EMT in human gliomas and the underlying mechanisms involved. Our results showed that TGF-β1 induced EMT of U87 and U251 cells, leading to a decrease in epithelial marker ZO-1 and an increase in mesenchymal markers N-cadherin and Vimentin. Moreover, TGF-β1 treatment resulted in a significant increase in the migratory and invasive abilities of the cells. However, treatment with DMC-HA effectively inhibited the augmented migration and invasion of glioma cells induced by TGF-β1. Additionally, DMC-HA inhibits TGF-β1-induced EMT by suppressing canonical Smad pathway and non-canonical TGF-β/Akt and Erk signalling pathways. These findings suggest that DMC-HA has potential therapeutic implications for gliomas by inhibiting EMT progression.

References

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

Luo Q, Luo H, Fu H, Huang H, Huang H, Luo K . [Curcumin suppresses invasiveness and migration of human glioma cells in vitro by inhibiting HDGF/β-catenin complex]. Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(8):911-916. PMC: 6765606. DOI: 10.12122/j.issn.1673-4254.2019.08.06. View

Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G . Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. Int J Mol Sci. 2019; 20(11). PMC: 6600373. DOI: 10.3390/ijms20112746. View

Wang H, Shi L, Wang Z . A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma. Front Oncol. 2021; 11:756817. PMC: 8602566. DOI: 10.3389/fonc.2021.756817. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Yang Z, Zhang C, Qi W, Cui Y, Xuan Y . GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. Exp Cell Res. 2018; 373(1-2):145-154. DOI: 10.1016/j.yexcr.2018.10.006. View

Zhang K, Fang T, Shao Y, Wu Y . TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 Signaling Axis Promotes Viability, Migration, Invasion and EMT of Hepatocellular Carcinoma Cells. Cancer Manag Res. 2021; 13:7087-7099. PMC: 8439444. DOI: 10.2147/CMAR.S297765. View

Zhao Z, Malhotra A, Seng W . Curcumin Modulates Hepatocellular Carcinoma by Reducing UNC119 Expression. J Environ Pathol Toxicol Oncol. 2019; 38(3):195-203. DOI: 10.1615/JEnvironPatholToxicolOncol.2019029549. View

Di Filippo L, Azambuja J, Dutra J, Luiz M, Duarte J, Nicoleti L . Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Eur J Pharm Biopharm. 2021; 168:76-89. DOI: 10.1016/j.ejpb.2021.08.011. View

10.

Marutha Muthu A, Cheah P, Koh C, Chew M, Toh Y, Looi L . Cyclooxygenase-2 (COX2) expression in adenocarcinoma surpasses that of squamous cell carcinoma in the uterine cervix. Malays J Pathol. 2017; 39(3):251-255. View

11.

Pu B, Zhang X, Yan T, Li Y, Liu B, Jian Z . MICAL2 Promotes Proliferation and Migration of Glioblastoma Cells Through TGF-β/p-Smad2/EMT-Like Signaling Pathway. Front Oncol. 2021; 11:735180. PMC: 8632809. DOI: 10.3389/fonc.2021.735180. View

12.

Zhang J, Cai H, Sun L, Zhan P, Chen M, Zhang F . LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res. 2018; 37(1):225. PMC: 6136228. DOI: 10.1186/s13046-018-0864-6. View

13.

Kang Y, Han S, Jeon H, Lee S, Lee J, Yoo S . Nogo receptor-vimentin interaction: a novel mechanism for the invasive activity of glioblastoma multiforme. Exp Mol Med. 2019; 51(10):1-15. PMC: 6813361. DOI: 10.1038/s12276-019-0332-1. View

14.

Pala A, Karpel-Massler G, Kast R, Wirtz C, Halatsch M . Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma. Cancers (Basel). 2013; 4(2):523-30. PMC: 3712701. DOI: 10.3390/cancers4020523. View

15.

Carro M, Lim W, Alvarez M, Bollo R, Zhao X, Snyder E . The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2009; 463(7279):318-25. PMC: 4011561. DOI: 10.1038/nature08712. View

16.

Wei L, Shao N, Peng Y, Zhou P . Inhibition of Cathepsin S Restores TGF-β-induced Epithelial-to-mesenchymal Transition and Tight Junction Turnover in Glioblastoma Cells. J Cancer. 2021; 12(6):1592-1603. PMC: 7890330. DOI: 10.7150/jca.50631. View

17.

Tao C, Luo H, Chen L, Li J, Zhu X, Huang K . Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma. Bioengineered. 2021; 12(1):4016-4031. PMC: 8806607. DOI: 10.1080/21655979.2021.1951927. View

18.

Peter K, Kar S, Gothalwal R, Gandhi P . Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research. Int J Mol Cell Med. 2022; 10(3):163-181. PMC: 8800460. DOI: 10.22088/IJMCM.BUMS.10.3.163. View

19.

Colella B, Faienza F, Di Bartolomeo S . EMT Regulation by Autophagy: A New Perspective in Glioblastoma Biology. Cancers (Basel). 2019; 11(3). PMC: 6468412. DOI: 10.3390/cancers11030312. View

20.

Pallasch F, Schumacher U . Angiotensin Inhibition, TGF-β and EMT in Cancer. Cancers (Basel). 2020; 12(10). PMC: 7601465. DOI: 10.3390/cancers12102785. View